Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016
Summary
Global Markets Direct’s, ‘Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016’, provides in depth analysis on Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted pipeline therapeutics.
The report provides comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27)
- The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects
- The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics
Reasons to buy- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
According to Global Markets Direct's, recently published report 'Coagulation Factor XI – Pipeline Review, H1 2016'; Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes.
Furthermore, Global Markets Direct says; Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.
The report 'Coagulation Factor XI – Pipeline Review, H1 2016' outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
- Introduction
- Global Markets Direct Report Coverage
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) Overview
- Therapeutics Development
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Stage of Development
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Therapy Area
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Indication
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Products Glance
- Late Stage Products
- Early Stage Products
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Companies
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Universities/Institutes
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Therapeutics Assessment
- Assessment by Monotherapy/Combination Products
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Companies Involved in Therapeutics Development
- Bayer AG
- Bristol-Myers Squibb Company
- Cambryn Biologics LLC
- eXithera Pharmaceuticals, Inc
- Ionis Pharmaceuticals, Inc.
- LegoChem Biosciences, Inc
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Drug Profiles
- AB-022 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BAY-1213790 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BMS-262084 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BMS-654457 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- coagulation factor XI (human) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- coagulation factor XI (human) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- IONIS-FXIRx - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule 2 to Inhibit Factor XIa for Thrombosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit Factor XIa for Cardiovascular - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit Factor XIa for Stroke and Thrombosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Dormant Projects
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Featured News & Press Releases
- Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
- Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022
- Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
- Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting
- May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
- Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma
- Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
- Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding
- Feb 02, 2011: Isis Initiates Phase I Clinical Trial Of ISIS-FXIRx To Treat Clotting Disorders
- Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for, H1 2016
- Number of Products under Development by Therapy Area, H1 2016
- Number of Products under Development by Indication, H1 2016
- Comparative Analysis by Late Stage Development, H1 2016
- Comparative Analysis by Early Stage Products, H1 2016
- Number of Products under Development by Companies, H1 2016
- Products under Development by Companies, H1 2016
- Number of Products under Investigation by Universities/Institutes, H1 2016
- Products under Investigation by Universities/Institutes, H1 2016
- Assessment by Monotherapy/Combination Products, H1 2016
- Number of Products by Stage and Mechanism of Action, H1 2016
- Number of Products by Stage and Route of Administration, H1 2016
- Number of Products by Stage and Molecule Type, H1 2016
- Pipeline by Bayer AG, H1 2016
- Pipeline by Bristol-Myers Squibb Company, H1 2016
- Pipeline by Cambryn Biologics LLC, H1 2016
- Pipeline by eXithera Pharmaceuticals, Inc, H1 2016
- Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
- Pipeline by LegoChem Biosciences, Inc, H1 2016
- Dormant Projects, H1 2016
- List of Figures
- Number of Products under Development for, H1 2016
- Number of Products under Development by Therapy Area, H1 2016
- Number of Products under Development by Top 10 Indication, H1 2016
- Comparative Analysis by Early Stage Products, H1 2016
- Assessment by Monotherapy/Combination Products, H1 2016
- Number of Products by Mechanism of Actions, H1 2016
- Number of Products by Stage and Mechanism of Actions, H1 2016
- Number of Products by Routes of Administration, H1 2016
- Number of Products by Stage and Routes of Administration, H1 2016
- Number of Products by Molecule Types, H1 2016
- Number of Products by Stage and Molecule Type, H1 2016